国金证券指出，截至23年末，公司管理或经营15家（同比增加3家）以肿瘤科为核心的医院。同时公司以并购+自建的方式不断扩大其医疗服务网络及业务规模。该行认为，内生外延双轮驱动下，公司业绩增长可期。Hygea Healthcare (06078) rose more than 11%. As of press release, it rose 10.46% to HK$29.05, with a turnover of HK$44.1561 million.
The Zhitong Finance App learned that Hygea Healthcare (06078) rose by more than 11%. As of press release, it had risen 10.46% to HK$29.05, with a turnover of HK$44.1561 million.
According to the news, Hygea Healthcare announced its 2023 annual results, with revenue of 4,077 billion yuan (same unit), up 27.57% year on year; net profit of 685 million yuan, up 42.14% year on year; adjusted net profit of 713 million yuan, up 17.53% year on year. Among them, the company's hospital business continued to grow well. In 2023, the company's hospital business achieved revenue of 3.89 billion yuan, a year-on-year increase of 29%, and a year-on-year increase of 35.4% after excluding the one-time impact of nucleic acid testing; the oncology business achieved revenue of 1,778 billion yuan, an increase of 23.6% over the previous year.
According to Guojin Securities, as of the end of '23, the company managed or operated 15 hospitals (an increase of 3 over the previous year) with oncology as the core. At the same time, the company continues to expand its medical service network and business scale through mergers and acquisitions+self-construction. The bank believes that with endogenous epitaxial two-wheel drive, the company's performance can be expected to grow.
